Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Capecitabine, and Bevacizumab in Elderly Metastatic Colorectal Cancer
NCT00120172Phase 2Terminated
- Sponsor
- Geriatric Oncology Consortium
- Start
- May 2005
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, capecitabine and bevacizumab in colorectal cancer (CRC), sponsored by Geriatric Oncology Consortium. Primary endpoint: Time to Progression. Started May 2005; status: terminated.
02
Drugs
oxaliplatincapecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00120172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120172.